**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-11 (cancelled).

12 (new). A compound selected from the group consisting of the azole derivatives having the general formula




including the salts thereof with pharmaceutically acceptable acids, the N-oxide forms thereof and the stereochemical isomers thereof, where:

A is N or CH;

Het is an aromatic heterocyclic radical containing one or more O or N atoms, optionally substituted with one or more 5- or 6-membered aromatic rings;

B is an alkanoic residue containing from 1 to 6 carbon atoms or is a residue of the formula




where:

R1 is hydrogen or a linear or branched alkyl residue containing from 1 to 6 carbon atoms and optionally substituted in one or more positions by hydroxyl groups;

R2 and R3, taken separately, are hydrogen or an alkyl with 1-4 carbon atoms or, taken together, are a divalent radical of the formula -CH=N-, -N=CH-, -CH=CH-, -CH2-CH2-.

13 (new). A compound according to claim 12 wherein A) is a nitrogen atom.

14 (new). A compound according to claim 12 wherein Het is selected from among: pyridine, pyridazine, pyrazine, pyrimidine, oxazole, pyrrole, pyrazole, imidazole, triazole and any corresponding fusion derivatives having two or more rings or with one or more benzene rings.

15 (new). A compound according to claim 12 wherein B) is formyl, acetyl or propanoyl.

16 (new). A compound according to claim 12 wherein B has the formula:




where R1 is hydrogen or a linear or branched alkyl residue containing from 1 to 6 carbon atoms and optionally substituted in one or more positions by hydroxyl groups.

17 (new). A compound selected from the group consisting of cis-4-{4-[4-{4-[2-(2-pyridinyl)-2-(1H-1,2,4-triazol-1-yl-methyl)-1,3-dioxolan-4-yl-methoxy]phenyl}-1-piperazinyl]-phenyl}-2-(1-methyl)-propyl-2,4-dihydro-3H-1,2,4-triazol-3-one, the salts thereof with pharmaceutically acceptable acids and the stereochemical isomers thereof.

18 (new). A method for treating fungal and/or bacterial infections, said method comprising administering a compound according to claim 12 to a patient in need of such a treatment.

19 (new). A method according to claim 18 for treating infections by Candida albicans, Candida glabrata, Candida parapsilosis, Aspergillus fumigatus.

20 (new). A pharmaceutical composition containing a compound according to claim 12, alone or in combination with at least one other active ingredient, together with one or more pharmaceutically acceptable excipients and/or auxiliary substances.

21 (new). A process for the production of a compound according to claim 12 in which a compound of the formula III




Formula (III)

where: A is N or CH and Het is an aromatic heterocyclic radical containing one or more O or N atoms, optionally substituted with one or more 5- or 6-membered aromatic rings;

is reacted with a compound of the formula



Formula (IV)

where: B is an alkanoic residue containing from 1 to 6 carbon atoms or is a residue of the formula



where: R1 is hydrogen or a linear or branched alkyl residue containing from 1 to 6 carbon atoms and optionally substituted in one or more positions by hydroxyl groups; R2 and R3, taken separately, are hydrogen or an alkyl with 1-4 carbon atoms or, taken together, are a divalent radical of the formula -CH=N-, -N=CH-, -CH=CH-, -CH2-CH2-.